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The protective effects of iodine on breast cancer have been postulated from epidemiologic evidence and described 
in animal models. The molecular mechanisms responsible have not been identified but laboratory evidence sug-
gests that iodine may inhibit cancer promotion through modulation of the estrogen pathway. To elucidate the role 
of iodine in breast cancer, the effect of Lugol’s iodine solution (5% I2, 10% KI) on gene expression was analyzed in 
the estrogen responsive MCF-7 breast cancer cell line. Microarray analysis identified 29 genes that were 
up-regulated and 14 genes that were down-regulated in response to iodine/iodide treatment. The altered genes 
included several involved in hormone metabolism as well as genes involved in the regulation of cell cycle pro-
gression, growth and differentiation. Quantitative RT-PCR confirmed the array data demonstrating that io-
dine/iodide treatment increased the mRNA levels of several genes involved in estrogen metabolism (CYP1A1, 
CYP1B1, and AKR1C1) while decreasing the levels of the estrogen responsive genes TFF1 and WISP2. This report 
presents the results of the first gene array profiling of the response of a breast cancer cell line to iodine treatment. 
In addition to elucidating our understanding of the effects of iodine/iodide on breast cancer, this work suggests 
that iodine/iodide may be useful as an adjuvant therapy in the pharmacologic manipulation of the estrogen 
pathway in women with breast cancer. 
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Introduction 
T h e h igh  r at e o f  b rea st  d ise ase  in  w o m en  w it h  
thyroid abnormalities (both dietary and clinical) sug-
gests a correlation between thyroid and breast physi-
ology [1-3]. In addition, women with breast cancer 
have larger thyroid volumes then controls [2]. Multiple 
studies suggest that abnormalities in iodine metabo-
lism are the likely link [4-7]. Additionally, the impact 
of iodine therapy for the maintenance of healthy breast 
tissue has been reported in both animal [4-7] and 
clinical studies [8, 9] yet the mechanisms responsible 
remain unclear. 
Iodide (I-) uptake is observed in approximately 
80% of breast cancers as well as fibrocystic breast dis-
ease and lactating breasts; however, quantitatively, no 
significant iodide uptake is reported in normal, 
non-lactating breast tissue [10]. Clinical trials have 
demonstrated that women with cyclic mastalgia [9] or 
fibrocystic disease [8] can have symptomatic relief 
from treatment with molecular iodine (I2). Iodine defi-
ciency, either dietary or pharmacologic, can lead to 
breast atypia and increased incidence of malignancy in 
animal models [11]. Furthermore, iodine treatment can 
reverse dysplasia which results from iodine deficiency 
[5]. Rat models using N-methyl-N-nitrosourea (NMU) 
and dimethyl-benz[a]anthracene (DMBA) to induce 
dysplasia and eventually carcinogenesis have shown 
that the presence of molecular iodine in the animal’s 
diet can prevent tumor formation; yet, when iodine is 
removed from the diet, these animals develop tumors 
at rates comparable to those of control animals [5, 7]. 
These data suggest that iodine diminishes early cancer 
progression through an inhibitory effect on cancer 
initiating cells. 
Evidence indicates that the impact of iodine 
treatment on breast tissue is independent of thyroid 
function. For example, iodine deficient rats given the 
thyroid hormone thyroxine (T4) did not achieve re-
duced tumor growth following NMU treatment sug-Int. J. Med. Sci. 2008, 5 
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gesting that the effect of iodine on tumor growth is 
independent of the thyroid gland or thyroid hormone 
[7]. Additionally, Eskin et al and others have reported 
that administration of molecular iodine has a greater 
impact on tumor growth than the equivalent dose of 
iodide [5-9]. Since the thyroid primarily utilizes iodide 
as opposed to iodine [5], this data supports the hy-
pothesis that iodine is not acting through the thyroid. 
In addition to differences in the metabolism of 
iodine, the mechanisms of iodine and iodide uptake 
appear to differ. While iodide uptake is essentially via 
the Sodium-Iodide Symporter (NIS) in the thyroid, 
data suggests that iodine uptake in the breast may be 
NIS-independent, possibly through a facilitated diffu-
sion system [12]. Together this data indicates that the 
effect of iodine on breast cancer progression is in part 
independent of thyroid function and suggests that 
iodine’s protective effect on breast cancer progression 
is elicited through its direct interactions with breast 
cancer cells. 
One proposed mechanism by which iodine may 
influence breast physiology and cancer progression is 
through an interaction with estrogen pathways. 
Qualitative changes in the estrogen receptor have been 
found in the breasts of iodine deficient rats compared 
to normal euthyroid animals suggesting that the iodine 
pathway may augment the synthesis of the estrogen 
receptor  α (ERα) [13]. Furthermore, when estro-
gen-responsive and estrogen-independent tumors 
were transplanted into mice, estrogen-responsive tu-
mors had higher radioactive iodine uptakes than es-
trogen-independent transplants [14]. Additionally, 
iodine deficiency induced atypia is worsened by es-
trogen addition [15]. Together, this data supports the 
hypothesis that an interaction exists between iodine 
and estrogen within the breast [16]. However, the pre-
cise molecular mechanisms responsible for this inter-
action remain unknown. We hypothesize that iodine 
effects breast physiology though an interaction with 
the estrogen pathway. 
To test our hypothesis, we analyzed the effects of 
Lugol’s iodine solution (5% I2, 10% KI) on global gene 
expression in the estrogen responsive MCF-7 breast 
cancer cell line. Analysis of the gene expression profile 
was used to evaluate potential mechanisms of action of 
iodine.  
Results 
1mM iodide/iodine does not impact cellular prolif-
eration or viability at 48 hours 
Lugol’s iodine solution, which contains 5.0% Io-
dine and 10% Iodide, was used to adjust standard 
RMPI 1640 medium to a concentration of either 1 mM 
or 5 mM Iodine/iodide. Medium was supplemented 
with all-trans-retinoic acid (tRA) and 17β-Estradiol 
(E2) for 24 hours prior to iodine treatment. Our data in 
figure 1 shows that at 48 hours, 1 mM iodine/iodide 
had no effect on cell proliferation or viability, relative 
to control cells. However, treatment with 5 mM io-
dine/iodide was toxic to the cells, inhibiting cell pro-
liferation and reducing cell viability to less than 5% of 
control cells (P<0.01). Since no significant change in 
proliferation or viability was observed with 1 mM io-
dine/iodide, this concentration was used for the gene 
array studies. 
 
Figure 1: 1 mM iodine/iodide does not impact cell viability or 
proliferation at 48 hours. MCF-7 cells were grown in 
RPMI-1640 supplemented with 1 µM tRA and 1 nM estradiol 
(control medium) or control medium supplemented with 
Lugol’s iodine solution (5% iodine, 10% iodide) to a concen-
tration of 1 mM iodine (1.0 mM iodine/iodide) or 5 mM iodine 
(5 mM iodine/iodide) for 48 hours and the effect on cell prolif-
eration (A) and cell viability (B) was analyzed. Significant 
decrease in proliferation and viability was observed in the 5 mM 
iodine/iodide condition. Relative change in cell proliferation (A) 
and relative change in viability (B) for the control condition was 
set to one. Standard deviation is shown. ** denotes P ≤ 0.01 
 
Interestingly, it has been reported that iodine 
alone can induce apoptosis at concentrations as low as Int. J. Med. Sci. 2008, 5 
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1µM [14], however we did not see cytotoxicity even at 
significantly higher (1mM) doses. Although the rea-
sons for this difference remain unknown, several pos-
sible explanations exist. First, it may reflect differences 
in the cell lines used. Second, the presence of 
all-trans-retinoic acid, and/or 17β-estradiol may pro-
tect the MCF-7 cells from the cytotoxic effects of iodine 
previously reported. Finally, since previous studies 
have all used iodine alone while we used a combina-
tion of iodine and iodide, it is possible that the pres-
ence of iodide protects the MCF-7 cells from the det-
rimental effects of iodine. Indeed, it has been reported 
that iodide up to 5mM did not have a cytotoxic effect 
on MCF-7 cells [14]. Furthermore, this may explain 
why breast cancers, which have increased NIS expres-
sion [17, 18] and increased iodide [18] uptake do not 
undergo apoptosis. 
Gene Expression Profiling 
Gene expression profiling was performed in trip-
licate on MCF-7 control cells and MCF-7 cells treated 
for 48 hours with medium supplemented with Lugol’s 
Iodine solution to 1mM iodine/iodide. As described in 
the methods, all cells were pretreated for 24 hours with 
tRA and 17ß-estradiol prior to beginning iodine 
treatments. Data normalization and analysis are de-
scribed in the Methods and Material section. Common 
genes with a mean change greater than two fold were 
considered significantly changed. Twenty-nine genes 
were up-regulated (Table 1A) and fourteen genes were 
down regulated-regulated (Table 1B).   
 
Table 1. MCF7 cells were treated with Lugol’s iodine solution or vehicle alone for 48 hr (see Methods and Materials for details). 
RNA was isolated and subjected to Microarray Analysis (see Methods and Materials for details). 29 genes were upregulated ≥ 
2.0-fold (A) and 14 genes were down regulated ≥ 2.0-fold (B) in response to treatment. Genes were than clustered into functional 
categories using the DAVID Bioinformatics Database Gene Functional Classification Tool (NIAID/NIH). The fold change in ex-
pression is relative to control cells. Bold genes were verified by qRT-PCR (Figure 2).  
A. 29 Genes that are Up-Regulated1 in Response to Iodine Treatment2 
Cell Cycle/Proliferation  Fold Change
NM_001673 ASNS  asparagine  synthetase  4 
L24498  GADD45A  growth arrest and DNA-damage-inducible, alpha3 2 
Steroid Metabolism 
NM_000104  CYP1B1  cytochrome P450, family 1, subfamily B, polypeptide 13 11.3 
NM_001353  AKR1C1  aldo-keto reductase family 1, member C13 6 
NM_000499  CYP1A1  cytochrome P450, family 1, subfamily A, polypeptide 13 2.5 
Transcription 
NM_003900 SQSTM1  sequestosome  1  2.8 
AB025432  TSC22D3  delta sleep inducing peptide, immunoreactor  2.6 
DNA repair 
NM_019058  DDIT4  DNA-damage-inducible transcript 4  2.2 
L24498  GADD45A  growth arrest and DNA-damage-inducible, alpha3 2.0 
Lipid Metabolism   
NM_000693  ALDH1A3  aldehyde dehydrogenase 1 family, member A3  3.2 
NM_004315  ASAH1  N-acylsphingosine amidohydrolase (acid ceramidase) 1  2.2 
tRNA synthesis 
NM_004184 WARS  tryptophanyl-tRNA  synthetase  3 
NM_002047 GARS  glycyl-tRNA  synthetase  2.3 
NM_003680 YARS  tyrosyl-tRNA  synthetase  2 
Other 
NM_021158  TRIB3  tribbles homolog 3 (Drosophila)  4 
NM_005218  DEFB1  defensin, beta 1  3.3 
NM_033197  C20orf114  chromosome 20 open reading frame 114  2.7 
NM_004753  DHRS3  dehydrogenase/reductase (SDR family) member 3  2.7 
NM_002083  GPX2  glutathione peroxidase 2 (gastrointestinal) 3 2.5 
NM_006636 MTHFD2  methylene  tetrahydrofolate  dehydrogenase  2.5 
AF104032  SLC7A5  solute carrier family 7, member 5  2.4 
NM_004864  GDF15  growth differentiation factor 15  2.2 
NM_000416  IFNGR1  interferon gamma receptor 1  2.1 
NM_002356  MARCKS  myristoylated alanine-rich protein kinase C substrate  2.0 
Function Unknown 
AK001064  LOC86026  hypothetical protein DKFZp434P055  3.5 
AK054816  ORAOV1  oral cancer overexpressed 1  3.0 
NM_006470  TRIM16  tripartite motif-containing 16  2.4 
AF245505  MXRA5  matrix-remodelling associated 5  2.3 
AL162069  LOC144501  hypothetical protein LOC144501  2.2 
BE884686  LTB4DH  leukotriene B4 12-hydroxydehydrogenase  2.1 Int. J. Med. Sci. 2008, 5 
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B. 14 Genes that are Down-Regulated4 in Response to Iodine Treatment2 
Estrogen responsive genes  Fold Change
NM_003225  TFF1  trefoil factor 1 (estrogen-inducible sequence) 3 -2.3 
NM_003881  WISP2  WNT1 inducible signaling pathway protein 23 -2.4 
Cell Cycle genes 
NM_003258  TK1  thymidine kinase 1, soluble  -3.7 
NM_002305  LGALS1  lectin, galactoside-binding, soluble, 1 (galectin 1)  -2.6 
NM_007019 UBE2C  ubiquitin-conjugating  enzyme  E2C  -2.5 
NM_001071 TYMS  thymidylate  synthetase  -2.3 
NM_053056  CCND1  cyclin D1 (PRAD1: parathyroid adenomatosis 1) 3 -2.0 
NM_002466  MYBL2  v-myb myeloblastosis viral oncogene homolog like 23 -2.2 
Cell Growth/Proliferation Genes 
NM_005264  GFRA1  GDNF family receptor alpha 13 -2.5 
NM_007161  LST1  leukocyte specific transcript 1  -2.5 
Ion Transport Genes 
NM_004669  CLIC3  chloride intracellular channel 3  -2.2 
Chromatin Organization 
NM_002105  H2AFX  H2A histone family, member X  -2.2 
Function Unknown 
NM_007173 PRSS23  protease,  serine,  23  -3.7 
NM_006408  AGR2  anterior gradient 2 homolog (Xenopus laevis)  -2.1 
1 Increase ≥ 2.0-fold relative to control 
2 Accession number is to left, followed by gene symbol, name, and fold change. 
3 Verified by QRT-PCR 
4 Decrease ≥ 2.0-fold relative to control
 
 
Figure 2: Quantitative RT-PCR confirmed the changes in gene 
expression identified by microarray analysis. RNA was isolated 
from control cell and cells grown in the presence of 1 mM iodine 
for 48 hours. QRT-PCR analysis of genes predicted by mi-
croarray analysis to be down-regulated (A) and up- regulated (B 
& C) in response to iodine treatment. Cyclophilin A was used as 
control for normalization. All 10 genes showed significant 
changes (P < 0.03) in response to iodine treatment in concor-
dance with the array data. The mRNA level in the control sam-
ples was set to 1 and the fold change is shown. In panel C control 
bar is not visible. Dark bars represent control samples while 
grey bars represent samples treated with 1.0 mM Iodine. Stan-
dard Deviation bars are shown.  
 
Included in the down-regulated genes were genes 
involved in cell cycle (LGALS1, UBE2C, TYMS, 
MYBL2, and CCND1) [19-25], cell 
growth/differentiation (GFRA1) [26], nucleotide syn-
thesis (TK1 and TYMS) [27, 28], and ubiquination and 
cyclin destruction (UBE2C) [19]. Up-regulated genes 
include genes involved in estrogen metabolism 
(CYP1A1, CYP1B1, AKR1C1) [29, 30], DNA repair 
(GADD45A and DDIT4) [31, 32], cell cycle and prolif-
eration (ASNS and GADD45A) [33, 34], tRNA synthe-
sis (WARS, GARS, YARS) [35-37] and transcription 
(SQSTM1 and DSIPI) [38, 39]. 
 The list was compared to a set of genes with ex-
perimentally or computationally determined estrogen 
responsive elements (EREs) in their promoter region 
[40]. Nine (32%) of our up regulated genes (GADD45A, 
CYP1B1, TSC22D3, DDIT4, ASAH1, YARS, DHRS3, 
SLC7A5 and MARCKS) and five (38%) of our down Int. J. Med. Sci. 2008, 5 
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regulated genes (TFF1, WISP2, TYMS, CCND1, and 
H2AFX) have putative EREs in their promoter region 
further supporting an interaction between io-
dine/iodide and the estrogen pathway. 
Quantitative RT-PCR confirmation of array data 
10 genes of interest (5 up-regulated gene and 5 
down-regulated genes) were chosen for quantitative 
RT-PCR confirmation. Up regulated genes included 
CYP1B1, AKR1C1, CYP1A1, GPX2, and GADD45A 
and the down regulated genes included GFRA1, TFF1, 
MYBL2, WISP2, and CCND1. Quantitative RT-PCR 
was run in triplicate and normalized to cyclophilin A. 
All ten genes demonstrated significant changes in 
steady state mRNA (p < 0.03) in response to 48 hr 
treatment with 1 mM iodine/iodide, confirming the 
accuracy of the array data (Figure 2). The two estrogen 
responsive genes (TFF1 and WISP2) showed a signifi-
cant decrease in mRNA expression levels (Figure 2A) 
while the estrogen metabolism genes (CYP1A1, 
CYP1B1, and AKR1C1) demonstrated a significant 
increase in mRNA levels (Figures 2B and C). 
Discussion 
As the body of evidence builds, the importance of 
iodine on the maintenance of healthy breast tissue and 
its role in carcinogenesis becomes clearer. Unveiling 
iodine’s mechanism of action is of crucial importance. 
Verifying the protective effects of iodine in breast 
cancer pathways will improve our understanding of 
breast cancer physiology and potentially lead re-
searchers toward the development of novel treatments 
or enhancements of current therapies. In this study we 
provide the first gene array profiling of an estrogen 
responsive breast cancer cell line demonstrating that 
the combination of iodine and iodide alters gene ex-
pression. Among the list of altered genes were several 
genes documented to be estrogen responsive such as 
TFF1 and WISP2. Furthermore, the list contained sev-
eral genes involved in the estrogen response including 
Phase I estrogen metabolizing enzymes (CYP1A1 and 
CYP1B) and Cyclin D1, a competitive inhibitor of 
BRCA1 [41]. 
Consistent with our initial hypothesis that io-
dine/iodide interacts with the estrogen pathway, we 
found that iodine/iodide altered mRNA expression of 
several genes involved in the estrogen pathway and 
down-regulated several estrogen responsive genes. 
Furthermore, many of the genes identified contain 
putative Estrogen Responsive Elements in their pro-
moter region. One potential mechanism in which io-
dine/iodide can repress the estrogen effect on cellular 
metabolism is through alterations in the Cytochrome 
P450 pathway. Our data shows that treatment with 
iodine and iodide increases the mRNA levels of Cy-
tochrome P450 1A1 (CYP1A1) and 1B1 (CYP1B1), two 
estrogen phase I estrogen metabolizing enzymes that 
oxidizes 17β-estradiol to 2-hydoxyestradiol (2-OH-E2) 
and 4-hydoxyestradiol (4-OH-E2), respectively. These 
catechol estrogens can be further oxidized to quinones. 
3,4-estradiol quinine, a metabolite of 4-OH-E2, has 
been shown to react with DNA forming de-purinating 
adducts resulting in genotoxicity [42], while data sug-
gests that 2-OH-E2 can be metabolized to 
2-methoxyestradiol, an estrogen metabolite with 
anti-proliferative effects [43]. The observed increase in 
the CYP1A1/CYP1B1 ratio may shift the direction of 
estrogen metabolism favoring 2-OH-E2 which may 
either directly affect proliferation through increasing 
2-methoxyestradiol, decreasing 3, 4-estradiol quinone 
or indirectly via the inactivation of E2. The importance 
of the CYP1A1/CYP1B1 ratio in-vivo is evident in the 
increased presence of 4-OH-E2 in breast cancer tissue 
compared to non breast cancer controls [44]. However, 
the regulation and interplay between CYP1A1, 
CYP1B1, other Phase I and II enzymes and estrogen is 
complex, being influenced by multiple factors and 
multiple polymorphisms, thus more data is required to 
illuminate the importance of these changes in response 
to iodine. 
In addition to affecting estrogen metabolism, io-
dine/iodide may also inhibit estrogen induced tran-
scription via increased BRCA1 activity. BRCA1 is a 
known inhibitor of ERα transcription while Cyclin D1 
is thought to enhance the estrogen response via a 
competitive inhibition with BRCA1 [41]. Our data 
demonstrates decreased Cyclin D1 mRNA which 
could result in decreased competitive inhibition of 
BRCA1 allowing BRCA1 to inhibit estrogen induced 
transcription. Increased transcription of GADD45A, 
CYP1B1, and CYP1A1 are consistent with increased 
BRCA1 activity [34, 45]. 
Either through its interactions with estrogen or 
through estrogen independent mechanisms, the com-
bination of iodine and iodide seems to have an impact 
on genes involved with cell growth (GFRA1 and 
GDF15), cell cycle (LGALS1, UBE2C, MYBL2, TYMS, 
CCND1, ASNS, GADD45A), and differentiation 
(GFRA1, GDF15) . Of particular interest is the 
down-regulation of GFRA1. GFRA1 has been shown to 
increase NUMB expression which in turn degrades 
NOTCH; the net result of decreased GFRA1 expression 
is increased NOTCH. NOTCH has been implicated in 
stem cell differentiation during breast development, 
preventing uncontrolled basal cell proliferation during 
alveolar development [46]. As such, iodine may play a 
crucial role during periods of breast maturation during 
puberty and pregnancy. Int. J. Med. Sci. 2008, 5 
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Finally, this data further supports the need for 
clinical studies involving the use of iodine/iodide in 
conjunction with current estrogen modulation thera-
pies. Despite the efficacy of current treatments of 
breast cancer with medications such as Tamoxifen, the 
development of resistant cancers remains critically 
important. It has been found that CCND1 
over-expression plays an important role in the devel-
opment of Tamoxifen resistant breast cancer [25, 
47-49]; our data shows that iodine/iodide treatment 
can decrease mRNA levels of CCND1. This provides 
two potential mechanisms by which iodine/iodide 
could enhance the efficacy of Tamoxifen therapy: 1) 
having an additive effect on estrogen inhibition and 2) 
inhibiting the expression of CCND1 thus preventing or 
slowing the development of Tamoxifen resistance.  
The results presented in this paper build on the 
substantial epidemiologic, clinical and cellular data 
regarding the actions of iodine in breast physiology. 
We suggest that the protective effects of iodine/iodide 
on breast disease may be in part through the inhibition 
or modulation of estrogen pathways. Data presented 
suggests that iodine/iodide may inhibit the estrogen 
response through 1) up-regulating proteins involved 
in estrogen metabolism (specifically through increas-
ing the CYP1A1/1B1 ratio), and 2) decreasing BRCA1 
inhibition thus permitting its inhibition of estrogen 
responsive transcription. These data open the way for 
further defining pathways impacted by the essential 
element, iodine, in the cellular physiology of extra-
thyroidal tissues, particularly the breast. 
 
Materials and Methods 
Cell lines.  
Human MCF-7 breast cancer cells (ATTC, Ma-
nassas, VA) were grown in RPMI 1640 supplemented 
with 10% fetal bovine serum, penicillin, and strepto-
mycin (Gemini Bio-Products, West Sacramento, CA) 
and incubated at 37˚C with 5% CO2. 
Iodine and estrogen treatments.  
24 hours prior to iodine treatment cells were 
grown in control medium consisting of RPMI 1640 
supplemented with 1 µM all-trans-retinoic acid (tRA) 
in DMSO vehicle and 1 nM 17ß-estradiol 
(Sigma-Aldrich, St. Louis, MO) in EtOH vehicle. 
DMSO and EtOH concentrations did not exceed 0.1% 
(v/v). Lugol’s iodine solution (Sigma-Aldrich, St. 
Louis, MO) containing 5% I2 and 10% KI was added to 
the experimental medium to a concentration of 1mM 
iodine/iodide. Cells were grown for an additional 48 
hours. 
Proliferation and Viability Assays.  
To evaluate the effects of iodine on proliferation, 
MCF-7 cells were plated on 96 well plates. Cells were 
pretreated with tRA and estradiol control medium and 
treated with iodine as described above. MTT prolif-
eration assay (ATTC, Manassas, VA) was performed in 
accordance with the manufacturer. To test cell viabil-
ity, cells were grown on a six well plates, trypsinized, 
stained using ViaCount® Reagents (Guava Technolo-
gies, Hayward, CA) and analyzed using flow cytome-
try (Guava EasyCyte Mini.) 
RNA isolation.  
Following iodine treatment, total RNA was iso-
lated using RNAeasy mini kits (Qiagen, Valencia, CA) 
according to the manufacturer. RNA was quantified 
using a Bio-Mini DNA/RNA/Protein Analyzer (Shi-
madzu Scientific Instruments, Inc.). 
Microarray Analysis.  
Microarray slides were provided by the Genomic 
Facility at Drexel University College of Medicine con-
taining 23,000 human 70mer oligos (Human Genome 
Oligo Set Version 2.0) on a glass slide. RNA amplifica-
tion and labeling was performed using the Mes-
sageAmp™ aRNA Amplification Kit (Ambion, Austin, 
TX). Equal micrograms of fragmented, labeled aRNA 
was hybridized to a cDNA microarray using Slyde-
Hybe Buffer #1 (Ambion, Austin, TX). After 24 hours 
of hybridization microarray slides were washed and 
scanned on Axon 4000B Dual Laser Slide Scanner 
(Molecular Devices, Sunnyvale, CA.). Data was ana-
lyzed using GenePix (Molecular Devices, Sunnyvale, 
CA.) disregarding signals with a signal to noise ratio < 
1 and a sum of the means <600. Three biological du-
plicates were then analyzed using the GenePix Auto-
Processor (GPAP) program. Pre-processing and nor-
malization of data was accomplished using R-project 
statistical environment (http://www.r-project.org) 
and Bioconductor (http://www.bioconductor.org) 
through the GPAP website 
(http://darwin.biochem.okstate.edu/gpap). The re-
sulting data was annotated and analyzed using the 
DAVID Bioinformatics Database Gene Functional 
Classification Tool (NIAID/NIH). Genes with a 
greater than 2 fold change in 2 or more arrays were 
considered significant. 
Quantitative RT-PCR.  
Primer probe sets were purchased from Applied 
Biosystems (Foster City, CA). Probes and Assay ID 
included Cytchrome P450 1A1 (CYP1A1; 
Hs00153120_m1), Cytochrome P450 1B1 (CYP1B1; 
Hs00164383_m1), Aldo-keto Reductase 1C1 (AKR1C1; 
Hs00413886_m1), Glutathione Peroxidase 2 (GPX2; Int. J. Med. Sci. 2008, 5 
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Hs00702173_s1), Growth Arrest and 
DNA-Damage-Inducible  α (GADD45A; 
Hs00169255_m1), trefoil factor 1 (TFF1; 
Hs00170216_m1), GDNF family receptor alpha 1 
(GFRA1; Hs00237133_m1), Cyclin D1 (CCND1; 
Hs00277039_m1), v-myb myeloblastosis viral onco-
gene homolog (avian)-like 2 (MYBL2; 
Hs00231158_m1), and WNT1 inducible signaling 
pathway protein 2 (WISP2; Hs00180242_m1). Quanti-
tative RT-PCR was performed using Brilliant 
QRT-PCR Master Mix kits (Stratagene, La Jolla, CA) 
and analyzed using the Mx3000P real-time PCR ma-
chine (Stratagene, La Jolla, CA). Cyclophilin A was 
used for normalization. 
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